XML 68 R27.htm IDEA: XBRL DOCUMENT v3.20.1
License and Asset Acquisitions (Tables)
 12 Months Ended
Dec. 31, 2019
Business Combinations [Abstract]  
Schedule of IPR&D Expense

The Company recorded the following IPR&D expense on the consolidated statements of operations (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

GB002

 

$

—

 

 

$

—

 

 

$

5,500

 

GB001

 

 

—

 

 

 

19,148

 

 

 

—

 

GB004

 

 

—

 

 

 

20,000

 

 

 

—

 

GB1275

 

 

1,000

 

 

 

7,501

 

 

 

—

 

Other preclinical programs

 

 

2,600

 

 

 

3,010

 

 

 

—

 

Total in process research and development

 

$

3,600

 

 

$

49,659

 

 

$

5,500